Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Aggarwal, Anup; Parai, Maloy K; Shetty, Nishant; Wallis, Deeann; Woolhiser, Lisa; Hastings, Courtney; Dutta, Noton K; Galaviz, Stacy; Dhakal, Ramesh C; Shrestha, Rupesh; Wakabayashi, Shoko; Walpole, Chris; Matthews, David; Floyd, David; Scullion, Paul; Riley, Jennifer; Epemolu, Ola; Norval, Suzanne; Snavely, Thomas; Robertson, Gregory T; Rubin, Eric J; Ioerger, Thomas R; Sirgel, Frik A; van der Merwe, Ruben; van Helden, Paul D; Keller, Peter; Böttger, Erik C; Karakousis, Petros C; Lenaerts, Anne J; Sacchettini, James C (2017). Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13. Cell, 170(2):249-259.e25.

Sirgel, Frederick A; Warren, Robin M; Böttger, Erik C; Klopper, Marisa; Victor, Thomas C; van Helden, Paul D (2013). The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS ONE, 8(3):e59414.

Sirgel, Frederick A; Warren, Robin M; Streicher, Elizabeth M; Victor, Thomas C; van Helden, Paul D; Böttger, Erik C (2012). embB 306 Mutations as Molecular Indicators to Predict Ethambutol Susceptibility in Mycobacterium tuberculosis. Chemotherapy, 58(5):358-363.

Sirgel, Frederick A; Warren, Robin M; Streicher, Elizabeth M; Victor, Thomas C; van Helden, Paul D; Böttger, Erik C (2012). gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 67(5):1088-1093.

This list was generated on Wed May 23 21:28:38 2018 CEST.